LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback